London-based Ternary Therapeutics has secured $4.4 million in seed funding to develop AI-designed “molecular glues” aimed at addressing chronic inflammation, a key driver of age-related decline. This investment, led by Paris-based VC daphni, reflects a growing confidence in tackling complex challenges within drug discovery, particularly in the realm of targeted protein degradation. Ternary’s innovative approach seeks to modulate protein interactions rather than simply inhibiting them, potentially transforming how we address inflammation and its associated diseases.

The implications for longevity medicine are significant, as chronic low-level inflammation, or “inflammaging,” is linked to various age-related conditions, from neurodegeneration to metabolic disorders. By harnessing AI and a closed-loop validation system, Ternary aims to create a reliable pipeline for drug discovery that could lead to effective therapies for healthier aging.

For professionals in the field, Ternary’s approach exemplifies the intersection of computational biology and therapeutic innovation. I encourage you to explore the full article for deeper insights into this promising development in longevity science.

Source: longevity.technology